Oral microbes linked to increased risk of pancreatic cancer https://cancerletter.com/clinical-roundup/20250919_8c/

FDA cracks down on direct-to-consumer ads, including the Hims & Hers Superbowl blitz https://cancerletter.com/cancer-policy/20250919_6d/

Ned Sharpless (@unclineberger.bsky.social): "There’s no correlation between what the president asks for and what Congress does. And so, what really matters, and it’s mattered all along, has been what’s Congress going to do." https://cancerletter.com/the-cancer-letter/20250919_1/

FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging https://cancerletter.com/drugs-and-targets/20250919_9d/

AACR (@theaacr.bsky.social)'s Margaret Foti: "Federal investments in cancer research are the reasons that today’s progress is possible and tomorrow’s breakthroughs are within reach." https://cancerletter.com/the-cancer-letter/20250919_3/

Yale receives renewed lung cancer SPORE grant from NCI (@yalecancer.bsky.social) https://cancerletter.com/in-brief/20250919_7d/

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial https://cancerletter.com/clinical-roundup/20250919_8b/

Paul W. Thurman (@columbiauniversity.bsky.social): "What is urgently needed is a new funding mechanism for the NCI that insulates it from the political whims of shifting administrations." https://cancerletter.com/letter-to-the-editor/20250919_4/

FDA approves selumetinib for pediatric neurofibromatosis indication https://cancerletter.com/drugs-and-targets/20250919_9c/

AACR (@theaacr.bsky.social) survey finds overwhelming public support for federal funding for medical and cancer research https://cancerletter.com/cancer-policy/20250919_6c/

"The primary task of the group is to provide recommendations to the NCAB on the Institute’s research priorities and on research conducted or supported by the Institute," said Dinah S. Singer in a letter to Working Group members. https://cancerletter.com/nci/20250919_2/

AACR (@theaacr.bsky.social) 2025 Cancer Progress Report: "The evidence is clear: federal investments in cancer research yield extraordinary returns in lives saved, suffering reduced, and hope restored.” https://cancerletter.com/the-cancer-letter/20250919_3/

FDA approves Bosaya and Aukelso, denosumab biosimilars, for osteoporosis https://cancerletter.com/drugs-and-targets/20250919_9b/

Frank McCormick to receive the $1M inaugural Stephenson Global Prize https://cancerletter.com/in-brief/20250919_7a/

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows https://cancerletter.com/clinical-roundup/20250919_8a/

"The NCI is really, really sturdy. And even with all the stuff that’s happened in the last six months, you can count on the NCI," said Kimryn Rathmell (@osucccjames.bsky.social), in conversation with Ned Sharpless. https://cancerletter.com/the-cancer-letter/20250919_1/

UTSW receives SPORE grant from NCI to study liver cancer https://cancerletter.com/in-brief/20250919_7c/

CDC’s ACIP makes changes to childhood vaccine recommendations in first meeting since Monarez’s ouster https://cancerletter.com/cancer-policy/20250919_6b/

George Weiner: "I advise the up-and-coming generation and other colleagues to follow the lead of those who have come before us. Use the uncertainty of the moment as a reason to double down on your passion." https://cancerletter.com/guest-editorial/20250919_5/

FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer https://cancerletter.com/drugs-and-targets/20250919_9a/

How today’s uncertainty can motivate young investigators to double down on their passion Lessons from my Studs Terkel boxed set Guest editorial by George J. Weiner https://cancerletter.com/guest-editorial/20250919_5/

Urgently needed: A funding mechanism to insulate cancer research from political whims. Letter to the editor by @columbiauniversity.bsky.social's Paul W. Thurman. https://cancerletter.com/letter-to-the-editor/20250919_4/

UCSF awarded $12M SPORE grant to study cancer outcomes for meningioma, prostate cancer, and breast cancer (@ucsfhealth.bsky.social) https://cancerletter.com/in-brief/20250919_7b/

Ousted CDC director Susan Monarez testifies before Senate HELP Committee https://cancerletter.com/cancer-policy/20250919_6a/

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at @unclineberger.bsky.social symposium https://cancerletter.com/the-cancer-letter/20250919_1/

AACR (@theaacr.bsky.social) Cancer Progress Report makes the case for federal investment in cancer research https://cancerletter.com/the-cancer-letter/20250919_3/

NCI releases names of members of ad hoc working group—filling the void left by BSA https://cancerletter.com/nci/20250919_2/

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows (@astra-zeneca.bsky.social) https://cancerletter.com/clinical-roundup/20250912_10d/

Ze’ev Ronai, MD: "We simply did not realize how important the environment is for tumor development and the enormous role played by immune responses and the tumor microenvironment." https://cancerletter.com/guest-editorial/20250912_2/

Neptune Society: "Bonnie chose to channel her experience into helping others. She founded the Bonnie J. Addario Lung Cancer Foundation (now known as the GO2 for Lung Cancer) and later the Addario Lung Cancer Medical Institute (ALCMI)" https://cancerletter.com/obituary/20250912_6

Caius Radu, Christine Mona, Amar Kishan, Beth Glenn, Mina Sedrak, William Lowry named program leaders at UCLA Health Jonsson CCC https://cancerletter.com/in-brief/20250912_9d/

Lori Dajose: "David Baltimore was awarded the Nobel Prize for his discovery that the genetic material of tumor viruses could make DNA from their RNA genome, changing the...perception that genetic information could only be transferred from DNA to RNA." https://cancerletter.com/obituary/20250912_4/

Everett E. Vokes: "Dr. Golomb’s impact on people and our department as a mentor has been tremendously positive. Harvey was not just a mentor but also a friend to many of us." https://cancerletter.com/obituary/20250912_5/

Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows https://cancerletter.com/clinical-roundup/20250912_10c/

NCAB approves five reissue concepts https://cancerletter.com/the-cancer-letter/20250912_7/

FDA advances rare disease drug development with new evidence principles https://cancerletter.com/cancer-policy/20250912_8d/

“We can live with a certain level of uncertainty, but we’ve really been hit with a tsunami, and not quite sure what is ahead,” Beverly Ginsburg Cooper said. https://cancerletter.com/podcastc/20250912_1/

FDA seeks academic and patient advocate research partners for oncology data analysis https://cancerletter.com/drugs-and-targets/20250912_11d/

Christina Cone named associate deputy director of Preston Robert Tisch Brain Tumor Center at Duke Health (@dukehealth.bsky.social) https://cancerletter.com/in-brief/20250912_9c/

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows (@astra-zeneca.bsky.social) https://cancerletter.com/clinical-roundup/20250912_10b/

"David Baltimore, co-recipient of the 1975 Nobel Prize in Physiology or Medicine and president emeritus and the Judge Shirley Hufstedler Professor of Biology at @caltech.edu, died on Sept. 6. He was 87." -Lori Dajose https://cancerletter.com/obituary/20250912_4/

At an earlier meeting, last June, NCAB voted in support of the formation of a new NCAB ad hoc working group that would focus on extramural research concepts and programs in the wake of the elimination of the BSA https://cancerletter.com/the-cancer-letter/20250912_7/

Bonnie Addario, lung cancer survivor and advocate, dies at 77. Obituary by Neptune Society https://cancerletter.com/obituary/20250912_6/

FDA grants Fast Track designation for CER-1236 in AML https://cancerletter.com/drugs-and-targets/20250912_11c/

Vinay Prasad regains role as FDA chief medical and scientific officer https://cancerletter.com/cancer-policy/20250912_8c/

"Look at where our understanding of cancer was...20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined."- Ze’ev Ronai, MD https://cancerletter.com/guest-editorial/20250912_2/

FDA grants Hernexeo (@boehringerglobal.bsky.social) Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC https://cancerletter.com/drugs-and-targets/20250912_11b/

"Bonnie rose to prominence as President of Olympian Oil & Commercial Fueling Network (CFN). In an industry dominated by men, she led with vision...breaking barriers for women in leadership and earning admiration for her tenacity & grace" -Neptune Society https://cancerletter.com/obituary/20250912_6

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows https://cancerletter.com/clinical-roundup/20250912_10a/

“It’s hard to plan, and try to make sure that what we’re doing in the cancer research space is going to be funded,” said Ben Ho Park, director of the Vanderbilt-Ingram Cancer Center. https://cancerletter.com/podcastc/20250912_1/